Skip to main content

Advertisement

SpringerLink
Log in

Establishment and characterization of a novel dedifferentiated chondrosarcoma cell line, SMU-DDCS, harboring an IDH1 mutation

  • Cell Line
  • Published:
Human Cell Aims and scope Submit manuscript

Abstract

Dedifferentiated chondrosarcoma (DDCS) is a high-grade subtype with a bi-morphic histological appearance of a conventional chondrosarcoma component and it can abruptly transition to a high-grade non-cartilaginous sarcoma. To better understand the biological features of DDCSs and to help develop new therapies, a novel DDCS cell line, SMU-DDCS, was established. Tissue from an open biopsy of a tumor resected from a 75-year-old patient was subjected to primary culture. The cell line was established and authenticated by assessing DNA microsatellite short tandem repeats. The cells maintained in monolayer cultures exhibited constant growth, spheroid formation, and high invasive capacity. Out of the four mice inoculated with SMU-DDCS cells, tumors developed in three mice after 2 weeks. R132C mutation was found in the IDH1 but not the IDH2 genomic DNA sequence of SMU-DDCS cells. SMU-DDCS cells exhibited low chemosensitivity to doxorubicin, methotrexate, and cisplatin. This SMU-DDCS cell line harboring an IDH1 mutation will be a useful tool for investigating DDCS development and for evaluating novel therapeutic agents against it.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

Data availability

Data are available from the corresponding author upon reasonable request.

Abbreviations

DDCS:

Dedifferentiated chondrosarcoma

IDH:

Isocitrate dehydrogenase

MTX:

Methotrexate

CDDP:

Cisplatin

DXR:

Doxorubicin

References

  1. Thorkildsen J, Taksdal I, Bjerkehagen B, Haugland HK, Børge Johannesen T, Viset T, et al. Chondrosarcoma in Norway 1990–2013; an epidemiological and prognostic observational study of a complete national cohort. Acta Oncol. 2019;58(3):273–82. https://doi.org/10.1080/0284186x.2018.1554260.

    Article  PubMed  Google Scholar 

  2. . WHO Classification of Tumours of Soft Tissue and Bone. Lyon: IARC Press; 2020. p. 370–90.

  3. Grimer RJ, Gosheger G, Taminiau A, Biau D, Matejovsky Z, Kollender Y, et al. Dedifferentiated chondrosarcoma: prognostic factors and outcome from a European group. Eur J Cancer. 2007;43(14):2060–5. https://doi.org/10.1016/j.ejca.2007.06.016.

    Article  PubMed  Google Scholar 

  4. Miao R, Choy E, Raskin KA, Schwab JH, Nielsen GP, Deshpande V, et al. Prognostic factors in dedifferentiated chondrosarcoma: a retrospective analysis of a large series treated at a single institution. Sarcoma. 2019;2019:9069272. https://doi.org/10.1155/2019/9069272.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Kudo N, Ogose A, Hotta T, Kawashima H, Gu W, Umezu H, et al. Establishment of novel human dedifferentiated chondrosarcoma cell line with osteoblastic differentiation. Virchows Arch. 2007;451(3):691–9. https://doi.org/10.1007/s00428-007-0426-3.

    Article  CAS  PubMed  Google Scholar 

  6. Oyama R, Kito F, Takahashi M, Sakumoto M, Shiozawa K, Qiao Z, et al. Establishment and characterization of a novel dedifferentiated chondrosarcoma cell line, NCC-dCS1-C1. Hum Cell. 2019;32(2):202–13. https://doi.org/10.1007/s13577-018-00232-2.

    Article  CAS  PubMed  Google Scholar 

  7. van Oosterwijk JG, de Jong D, van Ruler MA, Hogendoorn PC, Dijkstra PD, van Rijswijk CS, et al. Three new chondrosarcoma cell lines: one grade III conventional central chondrosarcoma and two dedifferentiated chondrosarcomas of bone. BMC Cancer. 2012;12:375. https://doi.org/10.1186/1471-2407-12-375.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Farges M, Mazeau C, Gioanni J, Ettore F, Denovion H, Schneider M. Establishment and characterization of a new cell line derived from a human chondrosarcoma. Oncol Rep. 1997;4(4):697–700. https://doi.org/10.3892/or.4.4.697.

    Article  CAS  PubMed  Google Scholar 

  9. Rey V, Menendez ST, Estupiñan O, Rodriguez A, Santos L, Tornin J, et al. New chondrosarcoma cell lines with preserved stem cell properties to study the genomic drift during in vitro/in vivo growth. J Clin Med. 2019. https://doi.org/10.3390/jcm8040455.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Monderer D, Luseau A, Bellec A, David E, Ponsolle S, Saiagh S, et al. New chondrosarcoma cell lines and mouse models to study the link between chondrogenesis and chemoresistance. Lab Invest. 2013;93(10):1100–14. https://doi.org/10.1038/labinvest.2013.101.

    Article  CAS  PubMed  Google Scholar 

  11. Li X, Dean DC, Ferreira A, Nelson SD, Hornicek FJ, Yu S, et al. Establishment and characterization of a novel dedifferentiated chondrosarcoma cell line DDCS2. Cancer Control. 2021;28:10732748211045274. https://doi.org/10.1177/10732748211045274.

    Article  PubMed  PubMed Central  Google Scholar 

  12. Yang L, Chen Q, Zhang S, Wang X, Li W, Wen J, et al. A novel mutated cell line with characteristics of dedifferentiated chondrosarcoma. Int J Mol Med. 2009;24(4):427–35. https://doi.org/10.3892/ijmm_00000249.

    Article  CAS  PubMed  Google Scholar 

  13. Casali PG, Bielack S, Abecassis N, Aro HT, Bauer S, Biagini R, et al. Bone sarcomas: ESMO-PaedCan-EURACAN clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29(Suppl 4):79–95. https://doi.org/10.1093/annonc/mdy310.

    Article  Google Scholar 

  14. Hompland I, Ferrari S, Bielack S, Palmerini E, Hall KS, Picci P, et al. Outcome in dedifferentiated chondrosarcoma for patients treated with multimodal therapy: results from the EUROpean bone over 40 sarcoma study. Eur J Cancer. 2021;151:150–8. https://doi.org/10.1016/j.ejca.2021.04.017.

    Article  CAS  PubMed  Google Scholar 

  15. Amary MF, Bacsi K, Maggiani F, Damato S, Halai D, Berisha F, et al. IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours. J Pathol. 2011;224(3):334–43. https://doi.org/10.1002/path.2913.

    Article  CAS  PubMed  Google Scholar 

  16. Pirozzi CJ, Yan H. The implications of IDH mutations for cancer development and therapy. Nat Rev Clin Oncol. 2021;18(10):645–61. https://doi.org/10.1038/s41571-021-00521-0.

    Article  CAS  PubMed  Google Scholar 

  17. Vuong HG, Ngo TNM, Dunn IF. Prognostic importance of IDH mutations in chondrosarcoma: an individual patient data meta-analysis. Cancer Med. 2021;10(13):4415–23. https://doi.org/10.1002/cam4.4019.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Zhu GG, Nafa K, Agaram N, Zehir A, Benayed R, Sadowska J, et al. Genomic profiling identifies association of IDH1/IDH2 mutation with longer relapse-free and metastasis-free survival in high-grade chondrosarcoma. Clin Cancer Res. 2020;26(2):419–27. https://doi.org/10.1158/1078-0432.Ccr-18-4212.

    Article  CAS  PubMed  Google Scholar 

  19. Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med. 2009;360(8):765–73. https://doi.org/10.1056/NEJMoa0808710.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Marcucci G, Maharry K, Wu YZ, Radmacher MD, Mrózek K, Margeson D, et al. IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study. J Clin Oncol. 2010;28(14):2348–55. https://doi.org/10.1200/jco.2009.27.3730.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

The authors would like to thank Akari Takahashi and Fuminori Daimon for technical assistance with the experiments.

Funding

This work was partly supported by grants from JSPS KAKENHI (20K09506 to M. Emori).

Author information

Authors and Affiliations

  1. Department of Orthopedic Surgery, Sapporo Medical University School of Medicine, West 16, South 1, Chuo- Ku, Sapporo, 060-8543, Japan

    Makoto Emori, Naoya Nakahashi, Yasutaka Murahashi & Junya Shimizu

  2. Departments of Pathology, Sapporo Medical University School of Medicine, West 16, South 1, Chuo- Ku, Sapporo, 060-8543, Japan

    Naoya Nakahashi, Akira Takasawa, Kenji Murata, Tomohide Tsukahara & Makoto Osanai

  3. Department of Surgical Pathology, Sapporo Medical University School of Medicine, West 16, South 1, Chuo- Ku, Sapporo, 060-8543, Japan

    Shintaro Sugita & Tadashi Hasegawa

  4. Department of Medical Oncology, Sapporo Medical University School of Medicine, West 16, South 1, Chuo- Ku, Sapporo, 060-8543, Japan

    Kohichi Takada

  5. Department of Musculoskeletal Anti-Aging Medicine, Sapporo Medical University, West 16, South 1, Chuo- Ku, Sapporo, 060-8543, Japan

    Kosuke Iba

Authors
  1. Makoto Emori
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Naoya Nakahashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Akira Takasawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Kenji Murata
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yasutaka Murahashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Junya Shimizu
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Tomohide Tsukahara
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Shintaro Sugita
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Kohichi Takada
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Tadashi Hasegawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Makoto Osanai
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Kosuke Iba
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Makoto Emori.

Ethics declarations

Conflict of interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Ethical approval

This study was approved by the Institutional Review Board of Sapporo Medical University (reference number 282-156). Written informed consent was obtained from the patient in accordance with the guidelines of the Declaration of Helsinki.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Emori, M., Nakahashi, N., Takasawa, A. et al. Establishment and characterization of a novel dedifferentiated chondrosarcoma cell line, SMU-DDCS, harboring an IDH1 mutation. Human Cell 36, 2195–2203 (2023). https://doi.org/10.1007/s13577-023-00944-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13577-023-00944-0

Keywords

Search

Navigation